131I Activity for Remnant Ablation in Patients with Differentiated Thyroid Cancer: A Systematic Review
Open Access
- 1 January 2007
- journal article
- review article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 92 (1) , 28-38
- https://doi.org/10.1210/jc.2006-1345
Abstract
Context: Radioiodine ablation of the thyroid remnant after thyroidectomy is commonly performed in the management of patients with differentiated thyroid cancer. Although many centers administer an activity of 100 mCi, there is uncertainty over using a lower activity. Objective: A systematic review of the published literature was used to compare the success rates of remnant ablation using approximately 30 mCi with approximately 100 mCi (1.1 vs. 3.7 GBq). Data Sources: Data were obtained from MEDLINE and EMBASE for the years 1966 to March 2006. Study Selection: All studies that reported rates of successful ablation associated with approximately 30 or approximately 100 mCi of radioiodine were reviewed. Data Extraction: Studies were based on reviews of patient case notes (n = 41), prospective cohorts (n = 12), and randomized trials (n = 6). We obtained the success of thyroid remnant ablation according to different administered activities of radioiodine. Where a study reported on two or more activities, the risk ratio of having a successful ablation (∼30 vs. ∼100 mCi) was calculated and combined in a meta-analysis. Data Synthesis: Observational studies confirmed the high ablation success rate (∼80%) using approximately 100 mCi, although 22% of studies reported a rate of 90% or greater. The pooled ablation success rate in these studies was 10% lower using 30 mCi compared with 100 mCi (95% confidence interval, 3–17%; P = 0.01). The meta-analysis of the randomized trials produced equivocal results. For example, the rate of successful ablation in patients given 30 mCi was 8% lower compared with 100 mCi (95% confidence interval, 29% lower or up to 20% greater, P = 0.58), consistent with there being no difference or that 30 mCi is much less effective. Conclusions: From the published data, it is not possible to reliably determine whether ablation success rates using 30 mCi are similar to using 100 mCi. Large randomized trials are needed to resolve the issue and guide clinical practice.Keywords
This publication has 54 references indexed in Scilit:
- European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epitheliumActa Endocrinologica, 2006
- Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines TaskforceThyroid®, 2006
- Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus reportActa Endocrinologica, 2005
- Patients with Differentiated Thyroid Carcinoma Benefit from Radioiodine Remnant AblationJournal of Clinical Endocrinology & Metabolism, 2004
- A Systematic Review and Metaanalysis of the Effectiveness of Radioactive Iodine Remnant Ablation for Well-Differentiated Thyroid CancerJournal of Clinical Endocrinology & Metabolism, 2004
- Second primary malignancies in thyroid cancer patientsBritish Journal of Cancer, 2003
- Radioiodine Treatment with 30 mCi after Recombinant Human Thyrotropin Stimulation in Thyroid Cancer: Effectiveness for Postsurgical Remnants Ablation and Possible Role of Iodine Content inl-Thyroxine in the Outcome of AblationJournal of Clinical Endocrinology & Metabolism, 2003
- Follow-up of differentiated thyroid cancer: comparison of multiple diagnostic testsNuclear Medicine Communications, 2000
- Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancerClinical Endocrinology, 2000
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986